智通财经网·2025-08-29 10:26Group 1 - The core point of the news is that Fosun Pharma has signed a licensing agreement with Aikeno for the exclusive rights to research, develop, produce, register, and commercialize the AC-201 molecule in China and Hong Kong, Macau for human disease diagnosis, prevention, and treatment [1] - Fosun Pharma will pay up to RMB 156 million to Aikeno, which includes upfront and milestone payments [1] - AC-201 is an oral small molecule JAK inhibitor developed by Aikeno, primarily aimed at autoimmune diseases, with its first indication (moderate to severe plaque psoriasis) having completed Phase II clinical trials in China [1] Group 2 - The collaboration aims to leverage the group's strengths in drug clinical development, registration, production, and commercialization to enrich the product pipeline in the autoimmune field and enhance the group's core competitiveness in this treatment area [2]